Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.conctc.2015.08.002

http://scihub22266oqcxt.onion/10.1016/j.conctc.2015.08.002
suck pdf from google scholar
C5935830!5935830!29736433
unlimited free pdf from europmc29736433    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid29736433      Contemp+Clin+Trials+Commun 2015 ; 1 (ä): 2-4
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A two-stage design with two co-primary endpoints #MMPMID29736433
  • Song JX
  • Contemp Clin Trials Commun 2015[Oct]; 1 (ä): 2-4 PMID29736433show ga
  • Two-stage designs are commonly used in phase II oncology trial to mitigate the risk of exposing patients to an inefficacious drug. Typically, the decision of moving into stage 2 enrollment is made based on response rate in stage 1 patients; and trials are designed in the hypothesis testing framework. When the primary objective of a trial involves more than one efficacy endpoints it is desirable to extend the two-stage design to a setting that accommodates two hypotheses while controlling overall type I and II errors (? and ?). In this manuscript, we propose a simple method of searching stopping boundaries of both hypotheses simultaneously that satisfy ? and ? constrains using binomial distribution. Several design characteristics of these selected boundaries are further examined in order to choose the most desirable design based on an objective function. Simulation is used to confirm the results. A trial design in metastatic breast cancer where both response rate and health-related quality of life are of interest is used as an example of the application of the proposed method. In conclusion, the proposed design is an extension of Simon Two-Stage Design. It can be applied to phase II oncology trials with two independent co-primary efficacy endpoints.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box